Both hepatitis B and hepatitis C are preventable and effective medicines are available to control hepatitis B and cure hepatitis C. Now more than ever we need to ensure that new infections are averted and those affected are connected to care before it is too late. Treatments must be made available to all that need them.Your continued support in helping us do this is greatly appreciated.

Federal Health Committee announces inquiry into hepatitis C: Health Committee inquiry marks 2015 as year to turn tide on hepatitis C epidemic

A House of Representatives Health Committee inquiry into hepatitis C should be a catalyst that turns the tide on the rising death toll from hepatitis C-related liver disease.  Hepatitis Australia today welcomed the announcement of an inquiry into hepatitis C, a blood-borne virus that affects more than 230,000 Australians and will claim more than 650 lives this year alone.

 “Many Parliamentarians are acutely aware of the looming tidal-wave of serious liver disease and preventable deaths caused by a lack of regular liver health checks and appallingly low hepatitis C treatment rates.  Today’s announcement shows real leadership by the House of Representatives Health Committee to tackle the problem head-on,” said CEO of Hepatitis Australia, Helen Tyrrell. Read more ...

Update: The Auckland Statement on viral hepatitis - Australian Progress Report 2014

The Auckland Statement was launched at the 8th Australasian Viral Hepatitis Conference in Auckland, New Zealand, in September 2012, and was endorsed by all the leading Australian and New Zealand hepatitis organisations as a blueprint for urgent action on on viral hepatitis. Targets were set for achievement by 2016, and this progress report is provided at the half-way point. This report revisits the targets set in the Auckland Statement and reviews them from the perspective of the Australian response. Download now. (PDF 394.15kb)

click to enlarge

Latest Data on Viral Hepatitis Released.

On 18 September The Kirby Institute released the HIV, viral hepatitis and sexually transmitted infections in Australia: Annual Surveillance Report 2014. The report presents a variety of data which is intended to inform Australia's response to blood borne viruses and STIs.  In a presentation at the 9th Australasian Viral Hepatitis Conference, Hepatitis Australia delivered a presentation which compared the Australian responses to viral hepatitis and HIV.  When looking at the data, it is clear Australia needs to elevate it's response to viral hepatitis to emulate the highly effective response to HIV.  A copy of the presentation report will be available on this site shortly. You can download a copy of the Annual Surveillance Report here


Media statement released, 22 August 2014:

PBAC decisions – a mixed bag for Australians living with Hepatitis C

simeprevir (Olysio)
Hepatitis Australia today welcomed the recommendation to add simeprevir (Olysio) to the Pharmaceutical Benefits Scheme (PBS) for the treatment of genotype 1 chronic hepatitis C.

sofosbuvir (Sovaldi)
Responding to the PBAC decision to reject an application to subsidise the antiviral medication sofosbuvir (Sovaldi), Ms Tyrrell said “it’s a sad day when access to game-changing therapy is denied. This is a bad outcome for people living with hepatitis C”. Read more - Download now. (PDF 245.43kb)


HCV Quest for People Living with Hepatitis C

A global patient survey which will reveal how HCV is treated around the world has been developed by the World Hepatitis Alliance.

If you are living with hepatitis C, please take a moment to complete this survey. By doing so, you will help to inform international policy makers, opinion-leading doctors and the pharmaceutical companies who develop the treatments about what it is really like to live with hepatitis C. 

For more information and to participate click here.

World Hepatitis Day, 28 July 

The World Hepatitis Alliance first coordinated World Hepatitis Day in 2008 in response to the concern that chronic viral hepatitis did not have the level of awareness, nor the political priority, seen with other communicable diseases such as HIV/AIDS, tuberculosis and malaria.

In 2010 the World Health Assembly endorsed July 28 as World Hepatitis Day and it became one of only four ‘World Health Days’ recognised by the World Health Organization.

At the global level, the World Hepatitis Alliance works in conjunction with the World Health Organization to coordinate World Hepatitis Day. Each year, July 28 provides a focus for individuals, community groups, clinicians and other supporters to run awareness-raising events. The thousands of events which take place each year help to raise awareness and influence action on viral hepatitis at both a local and a global level

Almost half a million Australians are now living with chronic hepatitis B and C. This year in Australia we want to highlight the importance of regular liver check-ups and push for the changes needed within the health system to ensure all people living with, hepatitis B and hepatitis C have access to regular liver check-ups as a standard part of their care plan.

To find out what is happening in Australia on World Hepatitis Day 2014 Click here 

Support Us

You can also donate directly to Hepatitis Australia. Please contribute to our aim of a world without viral hepatitis by making a tax deductible donation. Find out more

Hepatitis Australia is a non-government, not-for-profit organisation that became incorporated in 1997. We do not provide services to individuals. To locate hepatitis services in your area visit the services page or call the Info line on 1300 437 222. Our members consist of the state and territory hepatitis organisations and other key services providing hepatitis services.


Page Updated:  15 July 2014

National Info Line

1300 HEP ABC  
(1300 437 222)

Visit Now

Visit Now